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Abstract
Background: Nowadays, nosocomial infection with multidrug-resistant Acinetobacter is an important problem 
in the world, which is facing wide spectrum antibiotics and hence has become resistant.
Materials and Methods: In this study, positive cultures of Acinetobacter from one hundred clinical samples in 
seven hospitals from Tehran during 2012-2013 were collected for checking antibiotic susceptibility. Samples 
test with Ceftazidim, Cefepime, Amikacine and Imipenem by E-test and for Tazocin, Colistin and Tigecycline 
was performed with disk diffusion method.
Results: For Colistin 10 samples, and for Tazocin, 40 samples were performed by E-test method. Then 
boumannii species of bacteria and non-baumannii Acinetobacter were separated by PCR and antibiotic 
susceptibility testing was performed on them. 89% of Acinetobacter samples were boumannii species, which 
was isolated from respiratory secretions at ICU.
Conclusion: Boumannii and non-boumannii species of bacteria with a high percentage were resistant to 
Ceftazidim, Amikacine, Cefepime, Tazocin and Imipenem. All baumannii and non-boumannii Acinetobacter 
were sensitive to Colistin, were only 75% sensitive to Tigecycline, which is a new glycylcycline. Colistin and 
Tazocin results in samples limited to the E-test method were similar with disk diffusion.
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Introduction
Nosocomial infections are one of the health problems 
of modern societies, which are rising with unusual 
organisms. Acinetobacter, which is the main cause of 
nosocomial infections such as pneumonia and 
nosocomial pneumonia, is caused by mechanical 
ventilation. Acinetobacter species are becoming 
resistant to antibiotics. Acinetobacter formed 4% of 
cases of pneumonia in the intensive care unit (ICU) 
in 1986, 6% in 2003 and 7% in the years 1992 -1997 
in the United States and the rate is still increasing1. 
Resistant cases of Acinetobacter baumannii in the 
neonatal ICU2, and cases of osteomyelitis caused by 
multidrug-resistant Acinetobacter in Iraq have been 
reported3.
Overflow Acinetobacter infection during 1977-2000 
occurred in Palestine. During the 25 years before 
outbreak Acinetobacter resistance to antibiotics such 
as Aminopenicillins, Ureidopenicillin, first-generation 
Cephalosporins, Cephamycin, and most of the 
aminoglycosides and tetracycline was reported4. 
Acinetobacter prevalence of multidrug-resistant, 
which was 1.2% in 2002, reached to 9.7% in 20065 and 
at polyclonal genotype, the emergence of resistant 
strains in Israel during the years 2003-2008 is 
reported6. 
Acinetobacter outbreak in hospitals was mainly caused 
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by items such as respiratory care, water source of 
moisturizers and wound lavage system7.
The main site of infection with this pathogen, like 
other Gram-negative, is lower respiratory tract and 
urinary tract. Identification of Acinetobacter in the 
ICU is difficult since this pathogen has the ability of 
colonization, especially in skin, throat, and 
temporarily in tracheostomy patients8.
Acinetobacter infections, mostly progress towards 
bacteremia, septicemia also lower respiratory tract 
involvement with Acinetobacter, are the most 
common source of infection in regards to 
Acinetobacter progression towards bacteremia and 
septicemia9.
Taking into consideration the importance of the 
resistant Acinetobacter in nosocomial infection and 
overflow appearance of this kind of infections in 
various hospitals, health centers and in different 
periods of times and since Acinetobacter infection 
with antibiotic-resistant is important factor of 
hospital mortality, increased length of 
hospitalization, extra costs which in turn has adverse 
emotional, psychological effects on patients and their 
companions, health budget and has adverse are 
created. We intend to identify resistant Acinetobacter
and antibiotic resistance hence taking a positive step 
towards improving healthcare status, the quality of 
treatment and practitioners' knowledge about correct 
and timely use of antibiotics, in order to avoid 
creating more resistance species also we want to 
review antibiotic susceptibility status in Iran (Tehran) 
review.
Methods
This study has been a cross series survey which has 
been done on 100 samples during 2012-2013 periods. 
Our samples were patients admitted to the ICU, 
surgical, pediatric and etc. wards in Khatamolanbya, 
Parsian, Iranmehr, Milad, Loghman Hakim and 
Labbafinejad hospitals by observing the entry and 
exit rules of this study.
After receiving permission from the authorities of 
hospitals and laboratories, the samples of blood, 
urine, sputum and tracheal tube were collected from 
patients needed to be cultured and were sent to the 
hospital laboratories. Then after providing direct 
smear from the samples, they were taken to the 
culture medium immediately and were kept in the 
incubator. For culturing the clinical samples, Blood 
agar and EMB agar mediums were used. Grown 
Gram-negative samples were tested on the basis of 
certain characteristics of Acinetobacter pathogens. 
Through examination of oxidase activity (negative 
oxidase), the ability to move the germs in the SH2 and 
DAPI (without movement), growth in citrate (no 
growth), colonies form in the TSI (Triple Sugar Iron), 
samples were found positive for Acintobacter. These 
samples were sent to reference Laboratories (Milad 
hospital’s Microbiology Laboratory, Infectious 
Disease Research Center of Labbafinejad hospital) for 
susceptibility and antibiotic resistance examination. 
Also Acinetobacter samples were isolated from 
baumannii strains by PCR method.
Antibiotic susceptibility and resistance of Ceftazidime, 
Cefepime, Amikacin, Imipenem antibiotics were 
examined by E-test method through antibiotic strips of 
Zistmand company, and Tigecycline, Colistin and 
Tazocin antibiotics were investigated by disk diffusion 
method (since antibiotical strips were not available) 
though antibiotical disks of mast or oxoid company. 
10% of samples for Colistin and 40% of samples for 
Tazosin were examined by both E test and disk 
diffusion methods.
Acinetobacter Blood agar colonies were transferred by 
MAC method and standard, with 0.5 opacity 
McFarland standard to broth culture medium.  Then 
Acinetobacter colonies were transferred from 
Antibiogram culture to Mueller Hinton agar medium. 
Later Ceftazidime, Cefepime, Amikacin, Imipenem 
antibiotical strips were kept in MH agar medium at 
35°C for overnight (about 18 hours), and then 
antibiogram and susceptibility to antibiotics results 
were obtained from degrees and MIC’s on antibiotical 
strips. For Tigocycline and Tazocin antibiotics, the 
antibiotical discs were kept in MH agar medium for 
18-24 hours at 35°C then antibiogram results were 
obtained by disk diffusion methods and using special 
tables on the bases of CLSI standard. After obtaining 
Acintobacter antibiotical susceptibility and resistance 
results we used SPSS software and descriptive 
statistical methods to analyses these results.
Results
Of 100 Acinetobacter samples which were collected 
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within 6 months from seven hospitals in Tehran, we 
were able to get samples of respiratory secretions, 
wounds, catheters, urine, CSF, brain abscess. Besides 
we collected positive cultured samples of 
Acinetobacter from ICU, Burn, surgery, internal 
medicine, and neurology wards. Out of 100 samples 
we had only one case from one-year-old child. Most 
of the patients were male in age range of 1 to 87 
years old with an average of 46.2 years. The age 
distribution did not differ between males and 
females. Highest number of samples was from 
respiratory secretions and the least of them brain 
abscess (only one sample). 
Most of the Acinetobacter samples were isolated from 
ICU. The age average of patients in the ICU and the 
internal ward was 60 years and in the burn unit was 27 
years. Sample distributions based on Acinetobacter 
species according to gender variable, clinical 
specimens, and hospital wards are shown in figures 1-
6.  
To investigate antibiotic susceptibility of Imipenem, 
Ceftazidime, Cefepime Amikacin antibiotics we used 
the E-test method and disk diffusion test for Colistin, 
Tazocin and Tigecycline antibiotics. Tigecycline and 
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Table 3: Antibiotic susceptibility of Acinetobacter baumannii strains by E-test and disk diffusion methods.
IntermediateSensitiveResistant  Antibiotics  
0  0  100  ceftazidim  
0  2  98  cefepime
11  12  77  imipenem
0  0  100  amikacine
2  14  84  tazocin
0  100  0  colistin
20  76  4  tigecycline
A. baumannii; 89%
A. non baumannii; 
11%
A. baumannii A. non baumannii
Figure 1. Distribution of Acinetobacter by species
female; 30%
male; 70%
Figure 2. Distribution of Acinetobacter by sample’s sex
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Colistin were examined by MIC range of E-test and antibiotical susceptibility range of disk diffusion 
Table 4: Antibiotic susceptibility of Acinetobacter non- baumannii strains by E-test and disk diffusion methods.
IntermediateSensitiveResistant  Antibiotics  
0  0  100  ceftazidim  
0  9  91  cefepime
11  18  64  imipenem
0  0  100  amikacine
2  9  82  tazocin
0  100  0  colistin
























Figure 3. Typical Distribution of Acinetobacter baumannii in hospital wards
Table 5: Antibiotic susceptibility of Acinetobacter species generally by E-test and disk diffusion.
IntermediateSensitiveresistant  Antibiotics  
0  0  100  ceftazidim  
0  5.5  94.5  cefepime
14.5  15  64  imipenem
0  0  100  amikacine
5.5  11.5  83  tazocin
0  100  0  colistin

























Figure 4. Distribution of Acinetobacter baumannii clinical samples
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method, which the related results are shown in tables 
1-2. Out Of 100 Acinetobacter samples, 40 samples 
for Tazocin and 10 samples for colistin were done by 
E-test method. The results were 80% resistance for 
Tazocin (84% in the disk diffusion method) and 
100% sensitivity in Colistin case (100% sensitive in 
the disk diffusion method). The results of 
Antibiotical susceptibility of Acinetobacter 
baumannii and non-baumannii, gained from using E-
test for Ceftazidime, Cefepime, Imipenem and 
Amikacin and using the disk diffusion method for 
Tazocin, Colistin and Tigecycline antibiotics are 
shown in the tables 3-5.
Discussion
Today, in spite of increasing survival rate of patients 
due to advances in medical technology and better 
conditions of intensive care in the ICUs, we are 
facing with the problem of the emergence of 
pathogens resistant to several antibiotics and hospital 
infections. One of these problems is Acintobacter, 
which its infection in hospitals especially in ICUs has 
been reported in many countries2,6. Inappropriate 
prescription of highly used antibiotics for treatment of 
infections, has caused the emergence of multi-drug 
resistant pathogens including Acinetobacter, hence 
research results show the increasing resistance of 
Acinetobacter to highly used antibiotics29. Today we 
are facing with the problem of dominance of 
Acinetobacter baumannii14 which our study also 
reached to the same result. Same as other studies our 
research showed that Acinetobacter has the most 
relation with respiratory system and most of the
positive samples for Acinetobacters were obtained 
from respiratory secretions and the respiratory tract is 
the main source of Acinetobacter infection4,6,8. As with 
other studies, our study also reported the most positive 
culture Acinetobacter from the ICU. Factors such as 
longer residency of patients in ICU, the need to 











































Figure 6. Distribution of non-clinical samples of Acintobacter baumanni
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underlying disease conditions of patients have 
provided the possibility of resistant pathogens7. Most 
of the studies have analyzed the antibiotic sensitivity 
of Acinetobacter by measuring the MIC with Micro 
dilution broth method. Some studies have used E-test 
method to analyze antibiotic susceptibility to 
Tigecycline and Colistin19,22. 
Although other studies, which have been done in the 
years 1999-2001 and 2006, show the increasing 
resistance acinetobacter to Beta-lactam, Carbapenem 
and Amino-glycosides antibiotics, Acinetobacter has 
retained its sensitivity to Colistin12. Of course we do 
have some reports of heteroresistancy to Colistin 
among Acinetobacter strains17. Besides, genotypes of 
Acinetobacter baumannii resistant to Colistin and 
Polymyxin B have been identified21. Resistance to 
Colistin among enterobacteriaceae has been reported 
mostly for Stenotrophomonas maltophilia species 
and lower degree in Pseudomonas aeruginosa rather 
than in Acinetobacter13. In our study, the results of 
antibiotic sensitivity in Acinetobacter baumannii to 
Ceftazidime, Cefepime, Tazocin, Imipenem and 
Colistin antibiotics has been similar to the results of a 
study which has been done in Italy during 2004-
2005. In that study, 97.5% to Ceftazidime, 96.2% to 
Cefepime, 90% to Tazocin, 77.5% to Imipenem, 
3.7% to  Tigecycline and 1.2% to Colistin18. Our 
results have been also similar to the study, which has 
been done on antibiotical sensitivity to Acinetobacter 
baumannii with MIC method in Brooklyn, USA 
2006. In this study, 85% to Ceftazidime, Cefepime 
89%, Tazocin 80%, 63% to Imipenem and 3% to 
Colistin12. The result of another study on antibiotic 
sensitivity to Acinetobacter baumannii in Tehran 
during 2006-2005, which was performed by disk 
diffusion method, has been relatively similar to the 
results of our study. In that study, the Acinetobacter 
bumanii’s resistance has been 95.3% to Ceftazidime, 
62% Tazocin and 50.9% to Imipenem24. 
The results on antibiotical susceptibility for 
Ceftazidime, Cefepime and Tazocin in our study 
have been similar to the survey, which has been done 
on Acinetobacter baumannii in Iraq and Kuwait 
during 2003-2004. (The study was carried out with 
MIC method antibiotical sensitivity has been 83% to 
Ceftazidime, 78% Cefepime and 89% to Tazocin. 
But in that survey, antibiotical sensitivity to 
Imipenem has been 90%, which has significant 
difference with the results of our study16. In a study in 
Taiwan during the 1997-2001 Acinetobacter species 
has been 90.6% sensitive to Imipenem11, but in 2005, 
in Columbia, Acinetobacter resistant to Carbapenem 
with OXA-23 and OXA-51 genes were identified10. 
The different results obtained in these studies are due 
to several factors including time, climatic conditions, 
type of antibiotics used in that community and the 
underlying condition of patients. We also should 
consider mutations, which is happening in 
Acinetobacter baumannii gene and making it resistant 
to Carbapenem.
The results of our study on antibiotical sensitivity of 
Acinetobacter baumannii to Amikacin have significant 
difference with the other studies12,16,18,24. In a study 
done in Australia, bactericidal effect of Amikacin on 
sensitive and resistant Acintobacters to Colistin has 
been satisfactory15 which are in contradiction with our 
results. The result of this study has been only 
consistent with the survey done in Ahvaz (south west 
of Iran) by disk diffusion method in 2003-2004 which 
Acinetobacter was 100% resistance to Amikasin25. 
The reason for such a different result may perhaps be 
due to paitents’ underlying factors and their recent 
consumption of Amikasin.
In our study, Antibiotical sensitivity in the case of 
Colistin has been consistent with other studies except 
the cases, which heteroresistancy to Colistin has been 
reported, and studies, which have described 
Acinetobacter baumannii species resistance to Colistin 
from genetic point of view12,14,16,18,21,23.
The results on Colistin and Tazocin on limited 
samples, which have been performed by disk diffusion 
method and E-test method, have not been consistent. 
In E-test method (40 samples) 80% were resistant to 
Tazocin and in disk diffusion method 84% resistance 
to Tazocin were observed. All 10 samples, which were 
done by E-test method for Colistin, those were 
sensitive to it.
In studies, which have been done on the correlation 
between E-test and MIC results on Colistin they 
concluded, that at lower levels of MIC the correlation 
exists but for higher quantity of MIC the correlation 
did not be confirmed22. The results of our study on 
Acinetobacter baumannii antibiotic sensitivity to 
Tigecycline which was obtained by disk diffusion 
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method were to some extend similar to the results of 
Korean study for period 2004-2006(56% sensitivity), 
and with the report Journal of Antimicrobial 
Chemotherapy (JAC) in April 2007 (78% sensitive), 
and study done in Rome, Italy during 2004-2005 
(5/96% sensitive).
It should be mentioned that in the said studies the 
antibiotic sensitivity were done by MIC method 
13,18,24.
Although in the global program for survey of 
Acinetobacter species sensitivity to Tigecycline, 
some cases for high resistance to Tigecycline in 
Argentina has been reported. But it may be possible 
that overexpression of intrinsic multidrug efflux 
pump has reduced the susceptibility to Tigecyclin 
among Acinetobacter species19.
In studies, which were done on the correlation 
between E-test and MIC results for Tigecycline, the 
results showed a week correlation. This weak 
correlation was more obvious in species with higher 
resistance20.
Differences in antibiotic sensitivity results of our 
study with other studies are due to the patient 
underlying factors, consumption pattern of 
antibiotics, in the region, antibiotic resistance pattern 
in the region, and also the test methods. It should be 
mentioned that the Prescription pattern and dose of 
antibiotics used in the treatment Acinetobacter 
baumannii have important rules in the results 
obtained. 
And also as was resulted in a study done on VAP, in 
lung transplant patients, it is necessary to use 
Cefepime and Tigecycline high-dose intravenous in 
treatment of Acinetobacter baumannii infection29.
In our study, there were no significant differences in 
the results of Acinetobacter baumannii with non-
baumannii. In comparison with other studies, in our 
study we observed increasing trend in antibiotic 
resistance for Imipenem, Amikacin and Tazocin. 
Antibiotic resistance to Imipenem, which was 3% in 
the study done in England in 2000, and 40% in the 
study done in Tehran during 2005-2006, was 64% in 
our study 14,24. 
Antibiotic resistance to Tazocin, which was about 
5% in the study done in England in 2000, and 25% in 
the study done in Tehran during 2005-2006, was 
82% in our study. About Amicasin resistance, which 
was 18% in the study done in England in 2000, 45% in 
the study done in Tehran during 2005-2006, was 100 
% in our study. 
Ceftazidime resistance, which was 73% in the 2000 
British study, 70% in the study done in Tehran during 
2005-2006, 100% in our study14,24.
Due to high percentage resistance of baumannii and
non-baumannii strains to most antibiotics except 
Colistin and Tigecycline, there were no significant 
differences in the analysis of antibiotic sensitivity 
condition in respect to sample type or sample 
collection place, also it did not have any effect on 
decision making about a type of antibiotic for different 
infections.
There were some constraints in our study such as the 
impossibility of infection differentiation from 
colonization also due to 6 month time period for 
collecting samples and repeated passages on the 
samples it is possible that the conditions have been 
provided for more mutations in Acinetobacter species 
and their higher resistance to antibiotics.
Another constrain was lack of E-test Strip for 
Tigecycline, and limited number of E-test steeps for 
Tazocin and Colistin in Iran which had made the 
compression of the results of our study with other 
studies difficult. So it is necessary to adjust the tariffs 
to reduce the costs of needed materials. Besides we 
should try through differentiation Acinetobacter 
infection from colonization avoiding unnecessary 
treatments and retaining Acintobacter susceptibility to 
Colistin and Tigecycline in our region.
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